US 9662322
Laquinimod for the treatment of relapsing-remitting multiple sclerosis (RRMS) patients with a high disability status
granted A61KA61K31/47A61K31/4704
Quick answer
US patent 9662322 (Laquinimod for the treatment of relapsing-remitting multiple sclerosis (RRMS) patients with a high disability status) held by TEVA PHARMACEUTICAL INDUSTRIES, LTD. expires Mon May 25 2037 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.
Key facts
- Applicant
- TEVA PHARMACEUTICAL INDUSTRIES, LTD.
- Grant date
- Tue May 30 2017 00:00:00 GMT+0000 (Coordinated Universal Time)
- Expiration
- Mon May 25 2037 00:00:00 GMT+0000 (Coordinated Universal Time)
- Claims
- 28
- CPC classes
- A61K, A61K31/47, A61K31/4704, A61K38/215, A61K45/06